Thomas Catinazzo Sells 187,163 Shares of Relay Therapeutics (NASDAQ:RLAY) Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo sold 187,163 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $16.97, for a total value of $3,176,156.11. Following the completion of the sale, the chief financial officer owned 177,461 shares of the company’s stock, valued at $3,011,513.17. The trade was a 51.33% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Thomas Catinazzo also recently made the following trade(s):

• On Thursday, May 14th, Thomas Catinazzo sold 17,717 shares of Relay Therapeutics stock. The stock was sold at an average price of $12.86, for a total transaction of $227,840.62.
• On Tuesday, April 28th, Thomas Catinazzo sold 972 shares of Relay Therapeutics stock. The stock was sold at an average price of $14.79, for a total transaction of $14,375.88.
• On Tuesday, April 7th, Thomas Catinazzo sold 17,717 shares of Relay Therapeutics stock. The stock was sold at an average price of $13.01, for a total transaction of $230,498.17.
• On Thursday, April 9th, Thomas Catinazzo sold 1,800 shares of Relay Therapeutics stock. The shares were sold at an average price of $15.00, for a total transaction of $27,000.00.

Relay Therapeutics Stock Down 1.1%

Shares of RLAY opened at $17.83 on Friday. The stock has a market capitalization of $3.42 billion, a P/E ratio of -11.36 and a beta of 1.75. The firm has a fifty day simple moving average of $14.46 and a two-hundred day simple moving average of $11.11. Relay Therapeutics, Inc. has a twelve month low of $3.03 and a twelve month high of $18.94.

Relay Therapeutics (NASDAQ:RLAY) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.06). The business had revenue of $3.00 million for the quarter, compared to analyst estimates of $5.58 million. Sell-side analysts expect that Relay Therapeutics, Inc. will post -1.55 EPS for the current fiscal year.

Institutional Trading of Relay Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. SG Americas Securities LLC boosted its holdings in shares of Relay Therapeutics by 591.7% during the 4th quarter. SG Americas Securities LLC now owns 220,949 shares of the company’s stock valued at $1,869,000 after buying an additional 189,004 shares in the last quarter. Tudor Investment Corp ET AL purchased a new stake in shares of Relay Therapeutics in the 3rd quarter worth about $399,000. Sanctuary Advisors LLC bought a new position in shares of Relay Therapeutics in the 4th quarter worth about $1,203,000. Commodore Capital LP increased its stake in shares of Relay Therapeutics by 27.3% in the 3rd quarter. Commodore Capital LP now owns 17,000,000 shares of the company’s stock worth $88,740,000 after acquiring an additional 3,650,000 shares in the last quarter. Finally, Mayport LLC bought a new stake in Relay Therapeutics during the third quarter worth about $259,000. 96.98% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have commented on RLAY shares. Raymond James Financial reaffirmed a “strong-buy” rating on shares of Relay Therapeutics in a research report on Tuesday, May 19th. Citigroup reiterated an “outperform” rating on shares of Relay Therapeutics in a research report on Wednesday, May 20th. The Goldman Sachs Group boosted their target price on Relay Therapeutics from $13.00 to $22.00 and gave the company a “buy” rating in a research note on Tuesday, April 28th. HC Wainwright upped their target price on Relay Therapeutics from $25.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday, May 26th. Finally, Barclays raised their price target on Relay Therapeutics from $21.00 to $27.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 20th. Two research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $23.30.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.